James J. Harding

A multicenter pilot study of nivolumab with drug-eluting bead transarterial chemoembolization in patients with liver-limited hepatocellular carcinoma

Background Drug-eluting bead transarterial chemoembolization (deb-TACE) is a standard for liver-limited, locally advanced hepatocellular carcinoma (HCC) and may enhance response to immune checkpoint inhibition through tumor immune microenvironment modulation. We evaluated nivolum...